Collectively, these findings suggest that circUCK2(2,3) can activate TGFα–EGFR signaling, and sensitize HCC to the synergistic cytotoxic effect of lenvatinib and EGFR inhibitors. The gene discussed is EGFR; the disease is hepatocellular carcinoma.